

Strategic Research & Innovation Committee

minutes

Minutes of the Strategic Research & Innovation meeting held on 14th March 2023

Present:	Bob Burgoyne	Non-Executive Director (Chair)
	Louise Robson	Non-Executive Director
	Jane Tomkinson	Chief Executive Officer
	Prof Jay Wright	Clinical Lead for Research and Director of Research & Innovation
	Jonathan Mathews	Chief Operation Officer
	Karen Edge	Chief Finance Officer
	Prof Raphaela Kane	Pro Vice Chancellor, Faculty of Health, LJMU
In Attendance:	Catarina Teige	Interim Deputy Director of Research & Innovation
	Katie Fitzsimmons	Associate Director of Strategic Partnership
	Jennifer Ohlsson	Senior Executive Assistant (Minutes)
Apologies for Absence:	Jonathan Develing	Director of Strategic Partnerships
	Prof Reecha Sofat	Head of Department Pharmacology and Therapeutics, University of Liverpool

1. Apologies for Absence

Apologies noted above.

2. Declarations of Interest

No declarations of Interest noted at this meeting

Action

3. Minutes of the previous meeting

There were no previous minutes to approve at this meeting, due to being the first meeting of the Strategic R&I Committee.

4. Action log

There was no action log to update at this meeting, due to being the first meeting of the Strategic R&I Committee.

5. Strategic Research & Innovation Committee ToR

Strategic R&I Colleagues were asked to note the Terms of Reference circulated prior to the meeting and comments and question were welcomed.

LR suggested adding a specific overview of the commercial element of Research work, to the duties and responsibilities and it was agreed that 'Oversight of commercial arrangements' will be added to the duties and responsibilities of the Terms of Reference.

BB/JO

JW stated that the membership is very appropriate and added that a Board level approach to research is very welcome.

It was also agreed by the strategic R&I Colleagues to add Keith Wilson, Patient Research Ambassador to the membership of the meeting.

BB/JO

It was agreed by Strategic R&I Committee to approve the Terms of Reference provided the above changes are made.

6. Research Strategy Document

Strategic R&I colleagues were asked to note the Research Strategy Document and it was noted that the research strategy document requires formal Board approval.

Comments and questions were welcomed and JW requested further clarity and guidance on how the strategy matches up with the Innovation strategy. LR agreed that it would be helpful to see the Research Strategy and Innovation Strategy alongside each other.

JW stated that there is keenness to get the Research Strategy out there and added that changes in Liverpool around Research are currently very research and academia institute driven. JW added that this can then be dovetailed with the Innovation Strategy at a later date.

JT agreed and noted that Research and Innovation have moved at different paces at LHCH. JT noted the innovation agenda in relation to the Liverpool Partnerships and the broader ICB, however stated it would be preferable not to delay the launch of the Research Strategy, particularly in light of the LCSS review and the amalgamation of the CRNs.

It was agreed that JW will work on the Research Strategy Document and will then take to Board of Directors for approval. It was also agreed that

JW

when an Innovation strategy is finalised, both strategies will be reviewed together, to ensure they dovetail.

LR also suggested that it would be beneficial to see an implementation plan, including responsible officers and timeframe as a supporting document. It was agreed that an implementation plan will be drafted and will come to the next Strategic R&I Committee.

JW/CT

7. LCCS Review Update

JW provided colleagues with an LCCS review update and noted that there are two parts to the review.

JW stated that the 1st part of review is a data collection of achievements of the LCCS over the first four years (Feb 2019 – Feb 2023). This will look at papers and impact, higher degrees, fellow appointments and grants. JW confirmed that this work has been completed and has now been received. JW agreed to amalgamate this data into summary slides and use as an introduction to stakeholder events.

JW stated that the key to moving forward is taking what has been achieved and considering where the Trust goes next and what the aim is as a triumvirate of three organisations. There also needs to be a review of the structure and management of LCCS and a review of the strategic plans with added value and focus.

RK agreed that focus is needed and added that LCCS was not the only driver and is important that gaps and areas of excellence are looked at. RK also added that it is not automatic that this can determine whether new resources are focused as there are a multiplicity of agendas.

JT stated that there will need to be some consideration of what the LCCS review means for the relationship with LHP and the residual elements of LHP.

8. Ongoing Research Projects report

JW noted that research projects go through the Operational R&I Committee and there is also a clinical trials database.

It was agreed that ongoing research projects would be included on the agenda going forward

9. Planned New Research Projects report

It was agreed that planned research projects would be included on the agenda going forward.

10. Research Finance Report

JW informed colleagues that there is currently a piece of work being done to establish how much the Research Department needs to run each month. JW noted that the department have three sources of income; CRN, grants and commercial income and this income supports a number of vacancies. It was agreed that a finance report would come to

each Committee.

11. Partnership working and updates from partners

Chair confirmed that this item will remain on the agenda for an opportunity for colleagues to provide updates and allow discussion on issues or opportunities from any partnerships.

RK noted that the partnership with LHCH is much wider than research and it would be important to join this together. JW agreed that finding solutions to processes across the three organisations would be beneficial.

JT informed colleagues that one of the strengths that the Trust should see emerging is the around the developing focus on Research within the ICB.

12. Research news and key successes

Chair stated that one of the roles of this committee is to promote the Trust's research excellence and added that there is a need to ensure that the public are aware of the excellent research coming out of the Trust. JW noted that there has been a recent drive about promoting Research on social media and LR highlighted the importance of the Comms Teams working together to promote LHCH, UoL and LJMU.

13. Report on Innovation Agenda

Nothing to add at this meeting but there will be renewed focus going forward.

14. Minutes from the last operational R&I Committee

Strategic R&I Colleagues were asked to note the minutes from the previous Operational R&I Committee

Comments and questions were welcomed and it was agreed to formally re-name the R&I Committee to the Operational R&I Committee.

RK expressed interested in seeing the Terms of Reference for the Operational Research & Innovation Committee and it was agreed that the ToR for Operational R&I Committee would be circulated with the papers for the next meeting.

Date and time of next meeting:

Tuesday 16th May 2023, 2pm – 3.30pm, MS Teams

JO

JW/JO